Pergolide: long-term use in Parkinson's disease

Area of Science:

• Neurology
• Pharmacology

Background:

• Short-term studies indicate pergolide (dopamine agonist) benefits Parkinson's disease (PD) management alongside carbidopa-levodopa.
• Long-term efficacy and safety data for pergolide in PD are crucial.

Purpose of the Study:

• To evaluate the long-term (2.5-3 years) outcomes of pergolide therapy in Parkinson's disease patients.
• To assess sustained benefit and safety profiles in patients previously enrolled in a double-blind trial.

Main Methods:

• Open-label extension study of pergolide therapy following a double-blind trial.
• 41 Parkinson's disease patients were assessed for long-term efficacy and side effects.

Main Results:

• 24% of patients showed sustained substantial benefit throughout the 2.5-3 year follow-up.
• 56% of patients remained on pergolide, demonstrating considerable improvement over baseline.
• Carbidopa-levodopa dosage adjustments were often unnecessary, with most patients maintaining or reducing their dose.

Conclusions:

• Pergolide provides long-term therapeutic benefits for a significant proportion of Parkinson's disease patients.
• Initial responders to pergolide are more likely to experience sustained long-term advantages.
• Common side effects include confusion, hallucinations, and dose-related angina, manageable through dose adjustments.